BRPI0919073A2 - protease inhibitors - Google Patents

protease inhibitors

Info

Publication number
BRPI0919073A2
BRPI0919073A2 BRPI0919073A BRPI0919073A BRPI0919073A2 BR PI0919073 A2 BRPI0919073 A2 BR PI0919073A2 BR PI0919073 A BRPI0919073 A BR PI0919073A BR PI0919073 A BRPI0919073 A BR PI0919073A BR PI0919073 A2 BRPI0919073 A2 BR PI0919073A2
Authority
BR
Brazil
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Application number
BRPI0919073A
Other languages
Portuguese (pt)
Inventor
Bertil Samuelsson
Horst Wahling
Perola Johansson
Pia Kahnberg
Vladimir Ivanov
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BRPI0919073A2 publication Critical patent/BRPI0919073A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0919073A 2008-09-24 2009-09-24 protease inhibitors BRPI0919073A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0817425.2A GB0817425D0 (en) 2008-09-24 2008-09-24 Protease inhibitors
PCT/EP2009/062407 WO2010034789A1 (en) 2008-09-24 2009-09-24 Protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0919073A2 true BRPI0919073A2 (en) 2016-03-15

Family

ID=39952075

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919073A BRPI0919073A2 (en) 2008-09-24 2009-09-24 protease inhibitors

Country Status (10)

Country Link
EP (1) EP2350089A1 (en)
JP (1) JP2012503626A (en)
KR (1) KR20110059657A (en)
CN (1) CN102224155A (en)
AU (1) AU2009295899A1 (en)
BR (1) BRPI0919073A2 (en)
CA (1) CA2738025A1 (en)
EA (1) EA201170480A1 (en)
GB (1) GB0817425D0 (en)
WO (1) WO2010034789A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314503D0 (en) * 2013-08-13 2013-09-25 Medivir Ab Cysteine protease inhibitor salt
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
SE0400022D0 (en) * 2004-01-08 2004-01-08 Medivir Ab New compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
JP2012503626A (en) 2012-02-09
AU2009295899A1 (en) 2010-04-01
CN102224155A (en) 2011-10-19
EA201170480A1 (en) 2011-12-30
KR20110059657A (en) 2011-06-02
GB0817425D0 (en) 2008-10-29
WO2010034789A1 (en) 2010-04-01
EP2350089A1 (en) 2011-08-03
CA2738025A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
CY2020023I1 (en) BETA-LACTAMAS INHIBITORS
LTC2178888I2 (en) Protease inhibitors
BRPI0807547A2 (en) HYPERCYCLIC ASPARTIL PROTEASE INHIBITORS
BRPI0917808A2 (en) cmet inhibitors
CR10831A (en) ESPIRO KETONA ACETIL-CoA CARBOXILASA INHIBITORS
DK2041138T3 (en) PYRROLTRIAZINKINASE INHIBITORS
DK2024375T3 (en) Cyclopropyl-condensed indolobenzazepine-HCV-NS5B inhibitors
DK2421825T3 (en) AZETIDINYLDIAMIDES AS MONOACYLGYLERIC LIPPASE INHIBITORS
BRPI0918564A2 (en) inhibitors
DK2246336T3 (en) fibrosis inhibitor
BRPI0814797A2 (en) DNA-PK INHIBITORS
BR112012001070A2 (en) complement activation inhibitors
BRPI1011267A2 (en) protease inhibitors
DK2066662T3 (en) SERINHYDROLASE INHIBITORS
DK2240506T3 (en) IAP inhibitors
BRPI0922283A2 (en) cysteine protease inhibitors
EP2313426A4 (en) Novel protease inhibitors
BRPI0918966A2 (en) protease inhibitors
ATE522533T1 (en) PYRAZOLOPYRIMIDINONKINASE INHIBITOR
BRPI0919073A2 (en) protease inhibitors
BR112012003044A2 (en) cathepsin inhibitors c.
FI20075320A0 (en) New useful inhibitors
TH0801000834A (en) Heterocyclic inhibitors Aspartyl Protease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired